



Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” [Leukemia Res. 104 March (2021)]

Jacqueline S. Garcia^{a,*}, Ronan T. Swords^b, Gail J. Roboz^c, Meagan A. Jacoby^d, Guillermo Garcia-Manero^e, Wan-Jen Hong^f, Xiaoqing Yang^b, Ying Zhou^b, Uwe Platzbecker^g, David P. Steensma^a, Johannes E. Wolff^b, Pierre Fenaux^h

^a Dana-Farber Cancer Institute, Boston, MA, USA

^b AbbVie Inc., North Chicago, IL, USA

^c Weill Medical College of Cornell University and New York-Presbyterian Hospital, NY, NY, USA

^d Washington University School of Medicine, St. Louis, MO, USA

^e University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA


^f Genentech Inc., South San Francisco, CA, USA

^g Leipzig University Hospital, Leipzig, Germany

^h Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, Université de Paris, Paris, France

Since the publication of this article the authors have identified an error in Figure 1b. The original plot used the incorrect variable data for the Y-axis and this has now been corrected to match the corresponding X-axis (as shown below). This correction neither changes the interpretation of the data nor does it alter the overall conclusions of the study.

Corrected Figure 1b.



DOI of original article: <https://doi.org/10.1016/j.leukres.2021.106555>.

* Corresponding author.

E-mail address: Jacqueline.garcia@dfci.harvard.edu (J.S. Garcia).

<https://doi.org/10.1016/j.leukres.2021.106581>

Available online 23 April 2021

0145-2126/© 2021 The Author(s). Published by Elsevier Ltd. All rights reserved.